- Home
- ALT vs CLLS Comparison
ALT vs CLLS Comparison
Compare ALT & CLLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ALT | CLLS |
|---|---|---|
| Founded | 1997 | 1999 |
| Country | United States | France |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 415.3M | 374.2M |
| IPO Year | 2005 | 2014 |
Fundamental Metrics
Financial Performance| Metric | ALT | CLLS |
|---|---|---|
| Price | $3.55 | $3.58 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 2 |
| Target Price | ★ $16.00 | $8.50 |
| AVG Volume (30 Days) | ★ 2.8M | 32.4K |
| Earning Date | 06-10-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 25.37 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $41,000.00 | N/A |
| Revenue This Year | N/A | $40.37 |
| Revenue Next Year | $756,308.50 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 105.00 | N/A |
| 52 Week Low | $2.91 | $1.10 |
| 52 Week High | $7.73 | $5.48 |
Technical Indicators
Market Signals| Indicator | ALT | CLLS |
|---|---|---|
| Relative Strength Index (RSI) | 30.87 | 39.37 |
| Support Level | $3.39 | $3.41 |
| Resistance Level | $4.25 | $3.77 |
| Average True Range (ATR) | 0.24 | 0.17 |
| MACD | -0.10 | -0.02 |
| Stochastic Oscillator | 13.55 | 2.60 |
Price Performance
Historical ComparisonAbout ALT Altimmune Inc.
Altimmune Inc is a clinical-stage biopharmaceutical company focused on developing treatments for obesity, metabolic diseases, and liver diseases. Its product candidate, pemvidutide (formerly known as ALT-801), is a novel, investigational, peptide-based GLP-1/glucagon dual receptor agonist. Pemvidutide is currently in clinical development for obesity and metabolic-associated steatohepatitis (MASH). The company also plans to pursue additional indications for pemvidutide that leverage the differentiated clinical profile of pemvidutide.
About CLLS Cellectis S.A.
Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC product candidates in other therapeutic indications.